

Bibliographic Information: JP 2001 089368

Medicine compositions for treatment of integrin α 4-mediated cell adhesion-associated diseases. Sircar, Ila; Gudmundsson, Kristjan S.; Martin, Richard. (Tanabe Seiyaku Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho (2001), 88 pp. CODEN: JKXXAF JP 2001089368 A2 20010403 Patent written in Japanese.
Application: JP 2000-216898 20000718. Priority: JP 99-204581 19990719. CAN 134:275760 AN 2001:232516 CAPLUS

Patent Family Information

| Patent No. | Kind | Date | Application No. | Date |
|---------------|------|----------|-----------------|----------|
| JP 2001089368 | A2 | 20010403 | JP 2000-216898 | 20000718 |

Priority Application

| | | |
|----------------|---|----------|
| JP 1999-204581 | A | 19990719 |
|----------------|---|----------|

Abstract

The medicine compns. (I; A = arom. hydrocarbon ring; Q = binding linkage; N = 0, 1, 2; W = O, S, -CH=CH-, -N=CH-; Z = O, S; R₁, R₂, R₃ = H, halogen, (substituted)low alkyl; R₄ = tetrazolyl, carboxyl, etc.; R₅ = H, nitro, (substituted)amino, OH low alkanoyl, etc.; R₆ = (substituted)phenyl, etc.) and their pharmacol. acceptable salts are claimed for treatment of integrin 4-mediated cell adhesion-assocd. diseases, including asthma, diabetes, rheumatoid arthritis, inflammatory bowel disease, and digestive tract and other diseases assocd. with leukocyte infiltration in the epithelium (e.g. skin, urethra, bronchiole, synovial membrane and transplanted kidney, liver, heart, blood vessel, and nerve tissues, and pancreas and other diseases including psoriasis, atopic dermatitis, contact dermatitis, systemic lupus erythematosus, etc.). I were prepd., and their inhibitory effects on cell adhesion were tested in vitro.

